WO2011002423A3 - Solubility enhancing pharmaceutical composition - Google Patents

Solubility enhancing pharmaceutical composition Download PDF

Info

Publication number
WO2011002423A3
WO2011002423A3 PCT/TR2010/000124 TR2010000124W WO2011002423A3 WO 2011002423 A3 WO2011002423 A3 WO 2011002423A3 TR 2010000124 W TR2010000124 W TR 2010000124W WO 2011002423 A3 WO2011002423 A3 WO 2011002423A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
solubility enhancing
enhancing pharmaceutical
solubility
compositions
Prior art date
Application number
PCT/TR2010/000124
Other languages
French (fr)
Other versions
WO2011002423A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Priority to EP10757644A priority Critical patent/EP2448576A2/en
Publication of WO2011002423A2 publication Critical patent/WO2011002423A2/en
Publication of WO2011002423A3 publication Critical patent/WO2011002423A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is about pharmaceutical compositions having problems of solubility, the preparation method of these compositions and the medical use thereof.
PCT/TR2010/000124 2009-07-02 2010-06-25 Solubility enhancing pharmaceutical composition WO2011002423A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10757644A EP2448576A2 (en) 2009-07-02 2010-06-25 Solubility enhancing pharmaceutical composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR200905146 2009-07-02
TR2009/05146 2009-07-02

Publications (2)

Publication Number Publication Date
WO2011002423A2 WO2011002423A2 (en) 2011-01-06
WO2011002423A3 true WO2011002423A3 (en) 2011-03-03

Family

ID=43066962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2010/000124 WO2011002423A2 (en) 2009-07-02 2010-06-25 Solubility enhancing pharmaceutical composition

Country Status (2)

Country Link
EP (1) EP2448576A2 (en)
WO (1) WO2011002423A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063737A1 (en) * 2004-12-17 2006-06-22 Boehringer Ingelheim International Gmbh Combination therapy comprising telmisartan and hydrochlorothiazide
EP1797872A1 (en) * 2005-11-22 2007-06-20 Teva Pharmaceutical Industries Ltd Telmisartan-containing pharmaceutical compositions for oral intake
WO2007147889A2 (en) * 2006-06-23 2007-12-27 Krka, Tovarna Zdravil, D.D., Novo Mesto Preparation of telmisartan salts
US20090142398A1 (en) * 2007-11-21 2009-06-04 Pharmascience Inc. Novel pharmaceutical compositions comprising a disintegration matrix

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602127A (en) 1991-02-06 1997-02-11 Karl Thomae Gmbh (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
SI9210098B (en) 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
US5594003A (en) 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
DE4225756A1 (en) 1992-01-22 1994-03-10 Thomae Gmbh Dr K Benzimidazoles, medicaments containing these compounds and process for their preparation
US5614519A (en) 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
DE19901921C2 (en) 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphs of telmisartan, process for their preparation and their use in the manufacture of a medicament
DE10153737A1 (en) 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Crystalline sodium salt of telmisartan, process for its preparation and its use for the manufacture of a medicament
DE10244681A1 (en) 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh New solid telmisartan-containing pharmaceutical formulations and their preparation
EP1824833A2 (en) 2004-11-11 2007-08-29 LEK Pharmaceuticals D.D. Preparation of telmisartan salts with improved solubility

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063737A1 (en) * 2004-12-17 2006-06-22 Boehringer Ingelheim International Gmbh Combination therapy comprising telmisartan and hydrochlorothiazide
EP1797872A1 (en) * 2005-11-22 2007-06-20 Teva Pharmaceutical Industries Ltd Telmisartan-containing pharmaceutical compositions for oral intake
WO2007147889A2 (en) * 2006-06-23 2007-12-27 Krka, Tovarna Zdravil, D.D., Novo Mesto Preparation of telmisartan salts
US20090142398A1 (en) * 2007-11-21 2009-06-04 Pharmascience Inc. Novel pharmaceutical compositions comprising a disintegration matrix

Also Published As

Publication number Publication date
WO2011002423A2 (en) 2011-01-06
EP2448576A2 (en) 2012-05-09

Similar Documents

Publication Publication Date Title
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
WO2012021715A3 (en) Stable formulations of linaclotide
WO2008066899A3 (en) Nanoparticulate formulations and methods for the making and use thereof
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
WO2011077043A3 (en) Phenol derivatives and pharmaceutical or cosmetic use thereof
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
HK1154795A1 (en) Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
WO2009126688A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO2008057550A3 (en) Stabilization of vaccines by lyophilization
WO2009156462A3 (en) Organic compounds
WO2011019822A3 (en) Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2012049307A3 (en) Novel n-terminally modified insulin derivatives
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
WO2010054286A3 (en) Substituted hydroxyphenylamine compounds
WO2010147830A3 (en) Aminothiazole modulators of beta-3-adrenoreceptor
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
WO2009105969A8 (en) Epothilone analogues, their pharmaceutical compositions, their use and their preparations
WO2009094457A3 (en) Substituted benzhydrylethers
EP2583969A4 (en) Novel rhodanine derivatives, method for preparing same, and pharmaceutical composition for the prevention or treatment of aids containing the rhodanine derivatives as active ingredients
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
EP2361907A4 (en) The five crystal forms of the nicousamide, the preparation methods, the pharmaceutical compositions and the uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10757644

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2010757644

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010757644

Country of ref document: EP